In-House Pharmacy Benefit Flattens Costs, Keeps Employees on GLP-1s
08-10-2026 12:00 via pharmacypracticenews.com

In-House Pharmacy Benefit Flattens Costs, Keeps Employees on GLP-1s

figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By Gina ShawAfter Beth Israel Lahey Health (BILH) brought its employee prescription benefit in-house and began requiring employee
Read more »

Pharmacy news



Combination bnAbs Sustained Viral Suppression in Children After ART Interruption
Combination bnAbs Sustained Viral Suppression in Children After ART Interruption
Brief Caregiver Education Boosts TD Evaluation and Diagnosis
Brief Caregiver Education Boosts TD Evaluation and Diagnosis
FDA Approves Extended-Release Form of Olanzapine for Treatment of Schizophrenia
FDA Approves Extended-Release Form of Olanzapine for Treatment of Schizophrenia
FDA Approves Remibrutinib for Treatment-Resistant Symptomatic Dermographism
FDA Approves Remibrutinib for Treatment-Resistant Symptomatic Dermographism
Registry Data Support Treating Mild Tardive Dyskinesia
Registry Data Support Treating Mild Tardive Dyskinesia
Pharmacy-Led Revenue Cycle Work Closes Billing Gaps, Speeds Treatment
Pharmacy-Led Revenue Cycle Work Closes Billing Gaps, Speeds Treatment
Deutetrabenazine Response Can Emerge After 15 Weeks, Post Hoc Analysis Suggests
Deutetrabenazine Response Can Emerge After 15 Weeks, Post Hoc Analysis Suggests
FDA Approves Degevma, Biosimilar to Xgeva
FDA Approves Degevma, Biosimilar to Xgeva
Financial Success Hinges on Proactive Enterprise Planning
Financial Success Hinges on Proactive Enterprise Planning
AAM Report: Generics and Biosimilars Saved $496 Billion in 2025
AAM Report: Generics and Biosimilars Saved $496 Billion in 2025
Innovative Oral Anticancer Therapy Monitoring In Health-System Specialty Pharmacy
Innovative Oral Anticancer Therapy Monitoring In Health-System Specialty Pharmacy
Closing the Rx Gap Between Oncology Guidelines and Practice
Closing the Rx Gap Between Oncology Guidelines and Practice
The Ongoing Struggle of Sickle Cell Disease
The Ongoing Struggle of Sickle Cell Disease
AHA Comments on 340B Pending Legislation, Urges Barring Rebate Models
AHA Comments on 340B Pending Legislation, Urges Barring Rebate Models
Desktop versie